Novo Nordisk rose as much as 4% after England's drug price regulator recommended the use of its best-selling drug Wegovy to prevent heart attacks and strokes. Wegovy is mainly a weight loss treatment but it is also approved for reducing the risk of major cardiovascular events in people living with overweight or obesity. The new recommendation the National Institute for Health and Care Excellence (NICE), England's drug price regulator, will significantly expand access to Wegovy on the country's National Heal ...

Key TakeawaysUK’s NICE recommends Wegovy (NVO) for cardiovascular risk reduction in adults with obesity, paving the way for NHS integration by late April.U.S. Treasury rushes to launch a digital portal to process $166 billion in refunds for Trump-era tariffs recently ruled unlawful by the Supreme Court.Microsoft (MSFT) and Engine No. 1 are in exclusive talks for a $7 billion natural gas power project in Texas to support data centers.Australia’s S&P/ASX 200 surged 1.6% in early trade as Treasurer Chalmers pr ...

British drug-cost watchdog recommends use of Novo's Wegovy to lower heart risks | Reuters Exclusive news, data and analytics for financial market professionalsLearn more aboutRefinitiv Wegovy presentation is displayed in New Columbia, Pennsylvania, U.S., November 13, 2023. REUTERS/Hannah Beier/Illustration/File Photo Purchase Licensing Rights, opens new tab April 1 (Reuters) - UK's drug cost-effectiveness watchdog has recommended Novo Nordisk's (NOVOb.CO), opens new tabWegovy to reduce the risk of serious h ...

Eli Lilly and Novo Nordisk, the two companies that dominate the global market for GLP-1 weight loss and diabetes drugs, are each deploying artificial intelligence (AI) across different stages of drug development in ways that are beginning to reshape how fast new medicines reach patients.By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions .Compl ...

[music] We're back on Morning Trade Live. Let's focus on Novo Nordisk, the company announcing a new drug subscription [music] plan today. More on that in a second with Marley.But the chart has been nothing short of a disaster. The stock is trading near four-year lows and is [music] down more than 75% from its all-time high in late June of 2024. Look at that.So, that's the focus of the morning trade. Joining us now for a closer look, as we promised, is Marley. Good morning, Marley.just walk us through the de ...

The company is trying to win customers by offering a "lower, predictable monthly price†for its obesity drugs. ...

Novo Nordisk (NVO) on Tuesday announced a first-of-its-kind subscription program for its weight loss therapy Wegovy (semaglutide) available on telehealth platforms, including LifeMD (LFMD) and Hims & Hers (HIMS). As part of the program, cash-paying patients can choose 3-, 6-, or 12-month subscriptions ...

Novo Nordisk on Tuesday launched a multi-month subscription program for its Wegovy obesity drug products that aims to ensure cash-paying patients see lower, "predictable" monthly prices. Eligible patients can choose between three-, six- or 12-month subscriptions for the Wegovy injection or the two highest doses of the newly launched pill under the same brand name. Longer plans offer lower monthly pricing, and the company expects people to save up to $1,200 a year on the injection and as much as $600 a year ...

Novo Nordisk to launch discounted Wegovy subscriptions for self-pay patients in US | Reuters Exclusive news, data and analytics for financial market professionalsLearn more aboutRefinitiv The logo of pharmaceutical company Novo Nordisk is displayed in front of its offices in Bagsvaerd, Copenhagen, Denmark, February 4, 2026. REUTERS/Tom Little/File Photo Purchase Licensing Rights, opens new tab LONDON, March 31 (Reuters) - Novo Nordisk will launch a discounted subscription plan for U.S. Wegovy patients payin ...

Reporting by Yagnoseni Das in Bengaluru; Editing by Devika Syamnath Our Standards: The Thomson Reuters Trust Principles., opens new tab Purchase Licensing Rights Business Novo Nordisk further slashes prices of Ozempic, Wegovy in India to better compete as generics enter | Reuters Exclusive news, data and analytics for financial market professionalsLearn more aboutRefinitiv Boxes of Ozempic and Wegovy made by Novo Nordisk are seen at a pharmacy in London, Britain March 8, 2024. REUTERS/Hollie Adams Purchase ...